Full dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in China.

Arch Med Sci · 2019 · PMC6524190 · PMID 31110537

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

In our study, from the full dose group to the tapering and discontinuation group, the proportion of patients who maintained a response showed a decreasing trend (91.7%, 85.4%, and 72.9%).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.